Exclusive

Publication

Byline

Location

Some equity mutual funds earn dividends too; here's why it may not be credited to your bank account - why it happens?

New Delhi, Oct. 5 -- Equity mutual funds invest in shares of listed companies that may pay dividends to their shareholders. So, when a company in a mutual fund's portfolio declares a dividend, the fun... Read More


INTERNATIONAL TRADE ADMINISTRATION ISSUES NOTICE: METHIONINE FROM FRANCE, JAPAN, AND SPAIN: FINAL RESULTS OF THE EXPEDITED FIRST SUNSET REVIEWS OF THE ANTIDUMPING DUTY ORDERS

WASHINGTON, Oct. 5 -- International Trade Administration has issued a notice called: Methionine From France, Japan, and Spain: Final Results of the Expedited First Sunset Reviews of the Antidumping Du... Read More


MSMEs hit record 3.25 lakh in Valley

Srinagar, Oct. 5 -- Micro, small and medium enterprises (MSMEs) have hit a record 3.25 lakh in Kashmir. Primarily driving the valley's industrial economy, MSMEs account for roughly 65% of 5 lakh tota... Read More


Singapore Clinical Trial: A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects with Moderately to Severe... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamide Compared with ARPI or Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer Previously Treated with Abiraterone Acetate (Himalayas-1)

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Rinzimetostat (ORIC-944) in Combination with Darolutamid... Read More


Singapore Clinical Trial: An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent Mismatch Repair (MMR) Proficient Endometrial Cancer

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'An Interventional Phase 3, Open Label, Randomized Study To Evaluate Efficacy And Safety of PF-08634... Read More


Singapore Clinical Trial: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy Wit... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Vers... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Vers... Read More


Singapore Clinical Trial: A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)

Singapore, Oct. 5 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety a... Read More